发明公开
EP1794134A1 SUBSTITUIERTE 2-ANILINOPYRIMIDINE ALS ZELLZYKLUS -KINASE ODER REZEPTORTYROSIN-KINASE INHIBITOREN, DEREN HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL
审中-公开
取代的2-苯胺基嘧啶细胞周期激酶或受体酪氨酸激酶抑制剂，生产与应用，药物
- 专利标题： SUBSTITUIERTE 2-ANILINOPYRIMIDINE ALS ZELLZYKLUS -KINASE ODER REZEPTORTYROSIN-KINASE INHIBITOREN, DEREN HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL
- 专利标题（英）： Substituted 2-anilinopyrimidines as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors, production of said substances and use of the latter as medicaments
- 专利标题（中）： 取代的2-苯胺基嘧啶细胞周期激酶或受体酪氨酸激酶抑制剂，生产与应用，药物
-
申请号： EP05793571.0申请日： 2005-09-27
-
公开(公告)号： EP1794134A1公开(公告)日： 2007-06-13
- 发明人: CLEVE, Arwed , LÜCKING, Ulrich , WEST, Christopher , BRIEM, Hans , SIEMEISTER, Gerhard , KRÜGER, Martin , JAUTELAT, Rolf , LIENAU, Philip
- 申请人： Bayer Schering Pharma Aktiengesellschaft
- 申请人地址： Müllerstrasse 178 13353 Berlin DE
- 专利权人： Bayer Schering Pharma Aktiengesellschaft
- 当前专利权人： Bayer Schering Pharma Aktiengesellschaft
- 当前专利权人地址： Müllerstrasse 178 13353 Berlin DE
- 优先权： US613964P 20040929; DE102004049622 20041006
- 国际公布： WO2006034872 20060406
- 主分类号： C07D239/48
- IPC分类号： C07D239/48 ; C07D239/46 ; A61K31/505 ; A61P35/00
摘要：
The invention relates to pyrimidine derivatives of general formula (I), in which R1, R2, R3, R4, A and D are defined as cited in the description, said derivatives being used as inhibitors of cyclin-dependent kinases and VEGF receptor kinases. The invention also relates to the production of said substances and to their use as a medicament for treating various diseases. The inventive compounds have a reduced affinity to carbonic anhydrase 2.
信息查询
